HIV is more common in people with serious mental illness than in the general population, and people with HIV-positive status who also have schizophrenia experience worse outcomes — not because of HIV biology but because of fragmented care, missed diagnoses, and drug interactions that can be hard to manage without coordination. A 2001 study by Rosenberg and colleagues in the American Journal of Public Health found HIV prevalence in adults with severe mental illness at roughly 3%, compared with under 0.5% in the general population at the time (Rosenberg et al., 2001). Subsequent studies have found similar elevations, with substantial geographic variation.
HIV is several-fold more prevalent in serious mental illness than in the general population, mostly through shared risk environments — but with modern antiretroviral therapy and PrEP for prevention, HIV in schizophrenia is fully treatable and people on effective treatment cannot transmit the virus.
Why prevalence is higher
- Higher rates of injection drug use.
- Higher rates of unprotected sex during periods of illness, including during manic or psychotic episodes.
- Sex work as a survival strategy for people with serious mental illness who experience housing instability.
- Reduced access to prevention services and condoms.
- Lower HIV testing rates in psychiatric settings than in primary care.
The CDC's HIV epidemiology pages highlight that mental illness, substance use, housing instability, and HIV risk overlap heavily.
Screening and testing
The CDC recommends one-time HIV screening for all adults age 13–64 as part of routine care, and repeat testing at least annually for people with ongoing risk factors. The USPSTF makes a similar recommendation. Testing is straightforward — a finger-stick antibody test in 20 minutes, or a venous draw with results in 1–3 days. People with schizophrenia are tested at lower rates than the general population; integrated psychiatric/primary-care models close this gap.
Prevention: PrEP, PEP, and condoms
Pre-exposure prophylaxis (PrEP)
Daily oral PrEP (tenofovir disoproxil/emtricitabine, brand name Truvada; or tenofovir alafenamide/emtricitabine, Descovy) reduces HIV acquisition risk by over 99% with consistent use. Long-acting injectable cabotegravir (Apretude) is now available every two months. The CDC PrEP guidance outlines candidacy. PrEP is appropriate for HIV-negative people at substantial risk through sexual exposure or injection drug use.
Post-exposure prophylaxis (PEP)
A 28-day course of antiretrovirals started within 72 hours of a high-risk exposure can prevent HIV acquisition. Available through emergency departments, sexual health clinics, and many primary-care offices.
Condoms
Standard barrier protection remains effective.
Treatment: antiretroviral therapy (ART)
Modern ART is one of the success stories of medicine. With consistent treatment, viral load becomes undetectable, the immune system recovers, and life expectancy approaches that of HIV-negative peers. A person on effective ART with sustained undetectable viral load cannot sexually transmit HIV (the U=U message: undetectable equals untransmittable, supported by extensive trial data, including the PARTNER and HPTN 052 studies summarised by the CDC).
Most people are now treated with single-tablet once-daily regimens combining an integrase inhibitor with two nucleoside reverse transcriptase inhibitors — for example bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) or dolutegravir-based regimens. Long-acting injectables (cabotegravir/rilpivirine every 1–2 months) are an option for adherence challenges.
Interactions with antipsychotics
This is where coordination matters. Several antiretrovirals are CYP3A4 inhibitors (notably cobicistat-boosted regimens and ritonavir) and can substantially raise levels of antipsychotics metabolised by CYP3A4 — including quetiapine, lurasidone, ziprasidone, and pimavanserin. Pimozide is contraindicated with strong CYP3A4 inhibitors.
Conversely, some antipsychotics have minimal CYP-mediated interactions. The University of Liverpool HIV drug interactions database is the standard reference and should be consulted whenever ART is initiated, changed, or paired with a new antipsychotic. Pharmacist review at every regimen change is best practice.
Adherence with cognitive symptoms
HIV treatment adherence requirements have eased dramatically — once-daily single-tablet regimens are forgiving compared with the multi-pill, multi-time regimens of the 1990s. For people with significant cognitive symptoms, options include:
- Long-acting injectable cabotegravir/rilpivirine (every 2 months)
- Pill organisers and reminder apps
- Directly observed therapy in some intensive case management programs
- Embedded HIV care within ACT teams or community mental-health centres
Mental health screening for people with HIV
People with HIV have higher rates of depression, anxiety, and (in some studies) psychosis than the general population. HIV itself can cause neuropsychiatric symptoms, particularly with advanced disease. New psychiatric symptoms in someone with HIV always merit medical evaluation alongside psychiatric assessment.
You experience high fevers, unexplained weight loss, persistent diarrhoea, oral thrush, severe headache, new neurological symptoms, or rapid cognitive change — these may indicate uncontrolled HIV or an opportunistic infection.
Stigma and disclosure
The stigma of HIV remains substantial, and the stigma of schizophrenia is well documented. People living with both face a compounded burden. Disclosure to partners, family, and clinicians is personal and contextual. Resources from the HIVinfo portal, NAMI, and local AIDS service organisations can help frame those conversations.
The big picture
HIV in schizophrenia is now a story of two highly treatable conditions — both of which require consistent, integrated care to manage well. PrEP for prevention, single-tablet ART for treatment, and pharmacist-supported coordination of antipsychotic and antiretroviral regimens make the medical side relatively straightforward. The harder work, as in much of serious mental illness care, is in the system — getting screening into psychiatric settings, getting psychiatric expertise into HIV clinics, and supporting adherence across both regimens. When that works, people with HIV and schizophrenia can have undetectable viral loads, stable mental health, and a normal life expectancy.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.